Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Rare pancreatic tumors].

Der Pathologe·2021
Same author

Radiological evaluation of pancreatic cancer: What is the significance of arterial encasement >180° after neoadjuvant treatment?

European journal of radiology·2021
Same author

Impaired autophagy increases susceptibility to endotoxin-induced chronic pancreatitis.

Cell death & disease·2020
Same author

Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma.

International journal of cancer·2019
Same author

Validation of at least 1 mm as cut-off for resection margins for pancreatic adenocarcinoma of the body and tail.

The British journal of surgery·2018
Same author

[Structured Curricular Advanced Education in "Medical Assessment" : Combined Concept of DGNB, DGN, DGNC, and DGPPN].

Der Nervenarzt·2018

Related Experiment Video

Updated: Mar 12, 2026

Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

7.3K

[Pancreatic acinar neoplasms : Comparative molecular characterization].

F Bergmann1

  • 1Pathologisches Institut, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 224, 69120, Heidelberg, Deutschland. frank.bergmann@med.uni-heidelberg.de.

Der Pathologe
|November 4, 2016
PubMed
Summary

Pancreatic acinar cell carcinomas have distinct genetic profiles, differing from other pancreatic cancers. This study identifies new therapeutic targets like EGFR and HSP90 for these aggressive tumors.

Keywords:
Acinar cell carcinomaGeneticsNeoplasmsPancreasTargeted therapy

More Related Videos

Pancreatic Tissue Dissection to Isolate Viable Single Cells
08:04

Pancreatic Tissue Dissection to Isolate Viable Single Cells

Published on: May 26, 2023

4.2K
Mimicking and Manipulating Pancreatic Acinar-to-Ductal Metaplasia in 3-dimensional Cell Culture
08:16

Mimicking and Manipulating Pancreatic Acinar-to-Ductal Metaplasia in 3-dimensional Cell Culture

Published on: February 11, 2019

9.4K

Related Experiment Videos

Last Updated: Mar 12, 2026

Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

7.3K
Pancreatic Tissue Dissection to Isolate Viable Single Cells
08:04

Pancreatic Tissue Dissection to Isolate Viable Single Cells

Published on: May 26, 2023

4.2K
Mimicking and Manipulating Pancreatic Acinar-to-Ductal Metaplasia in 3-dimensional Cell Culture
08:16

Mimicking and Manipulating Pancreatic Acinar-to-Ductal Metaplasia in 3-dimensional Cell Culture

Published on: February 11, 2019

9.4K

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Pancreatic acinar cell carcinomas (PACCs) are aggressive neoplasms with limited treatment options.
  • The molecular drivers of PACCs and their precursor lesions remain largely unknown.
  • Understanding the genetic landscape of PACCs is crucial for developing targeted therapies.

Purpose of the Study:

  • To cytogenetically and molecularly characterize pancreatic acinar cell carcinomas (PACCs).
  • To identify candidate genes and therapeutic targets in PACCs and other pancreatic neoplasms.
  • To investigate the neoplastic nature of acinar cell cystadenomas.

Main Methods:

  • Comparative genomic hybridization (CGH) for cytogenetic analysis.
  • Molecular and immunohistochemical analyses of tumor samples.
  • Functional analyses of cell lines and mitochondrial DNA sequencing.

Main Results:

  • PACCs exhibit a microsatellite stable, chromosomal unstable genotype, distinct from pancreatic ductal adenocarcinomas and neuroendocrine neoplasms.
  • Candidate genes (e.g., DCC, c-MYC) and therapeutic targets (e.g., EGFR, L1CAM, HSP90) were identified in PACCs.
  • L1CAM is implicated in pancreatic ductal adenocarcinoma tumorigenesis; EGFR and HSP90 inhibitors show anti-tumor effects in neuroendocrine neoplasms.
  • Acinar cell cystadenomas appear to be non-neoplastic, reactive lesions.

Conclusions:

  • PACCs possess unique genetic alterations that differentiate them from other pancreatic cancers.
  • Identified therapeutic targets like EGFR and HSP90 offer potential treatment strategies for pancreatic neoplasms.
  • Acinar cell cystadenomas are likely non-neoplastic, suggesting a need to reclassify these lesions.